HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Y 27632

RN given for di-HCl salt; inhibits Rho-associated protein kinase; inhibits calcium sensitization to affect smooth muscle relaxation; structure in first source

Also Known As:

N-(4-pyridyl)-4-(1-aminoethyl)cyclohexanecarboxamide; Y 27632, (4(R)-trans)-isomer; Y 27632, (4(S)-trans)-isomer; Y 27632, (trans)-isomer; Y 27632, dihydrochloride, (4(R)-trans)-isomer; Y-27632; Y27632

Networked: 270 relevant articles (25 outcomes, 24 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Thorlacius, Henrik: 6 articles (05/2015 - 06/2009)
2.	Jankov, Robert P: 5 articles (06/2015 - 02/2008)
3.	Koizumi, Noriko: 4 articles (09/2015 - 07/2011)
4.	Okumura, Naoki: 4 articles (09/2015 - 07/2011)
5.	Kinoshita, Shigeru: 4 articles (09/2015 - 07/2011)
6.	Kantores, Crystal: 4 articles (06/2015 - 02/2008)
7.	McNamara, Patrick J: 4 articles (06/2015 - 02/2008)
8.	Filippi, Sandra: 4 articles (05/2014 - 05/2007)
9.	Morelli, Annamaria: 4 articles (05/2014 - 05/2007)
10.	Maggi, Mario: 4 articles (05/2014 - 05/2007)

Related Diseases

1.	Inflammation 09/01/2013 - "Finally, inactivation of RhoA signaling in the dKO mice with Y-27632 improved muscle regeneration and reduced the expression of BMPs, inflammation, HO, and intramyocellular lipid accumulation in both skeletal and cardiac muscle. " 07/01/2008 - "The present study addresses the effects of pretreatment with inhaled Y-27632 on the severity of the allergen-induced EAR and LAR, the development of AHR after these reactions, and airway inflammation. " 01/01/2015 - "Y-27632 is associated with corticosteroid-potentiated control of pulmonary remodeling and inflammation in guinea pigs with chronic allergic inflammation." 05/01/2003 - "Oral administration of Y-27632 in rats significantly reduced the colonic inflammation. " 11/01/2009 - "The Rho/ROCK pathway plays an important role in the progression of CAN, and specific inhibition of Rho activity by Y-27632 showed favorable effects on blocking renal interstitial inflammation and fibrosis, thus efficiently retarding the development of CAN, which might provide us with a novel strategy to improve long-term renal graft survival."
2.	Anoxia (Hypoxia) 12/01/2003 - "Accordingly, during hypoxia, an ROK inhibitor, Y27632, was less effective in relaxing ET-1-precontracted strips. " 08/01/2011 - "Protective effects of Y-27632 on hypoxia/reoxygenation-induced intestinal injury in newborn rats." 05/01/2015 - "In normoxic PA, KMUP-1A/Y27632 (10μM) increased eNOS and reduced ROCK II. ROCK II/reactive oxidative species was increased and eNOS was reduced after long-term hypoxia for 21 days. " 12/01/2010 - "To test these hypotheses, NO production and endothelial barrier function were determined in fetal PAEC under baseline hypoxia and following exposure to normoxia with and without treatment with Y-27632, a specific pharmacological inhibitor of ROCK. " 03/01/2009 - "THG1603 and Y-27632 treatment also attenuated the adverse effects of hypoxia on RGC-5 neurite outgrowth, and their intravitreal administration prevented OIR-induced RGC loss. "
3.	Muscle Spasticity (Spastic) 08/04/2000 - "The topical application of Y-27632, a specific inhibitor of Rho-kinase, to the exposed spastic basilar artery on day 7 induced a dose-dependent dilation, and the intensities of vasospasm and the phosphorylation of MBS and MLC were simultaneously decreased by 10 micromol/L Y-27632, although the decrease in MBS phosphorylation was more marked than the decrease in MLC phosphorylation. " 06/01/2002 - "However, relaxations to Y-27632 were not significantly greater in endothelin-1 constricted spastic vessels initially relaxed with the endothelin converting enzyme inhibitor, phosphoramidon, as compared to endothelin-1 constricted control vessels. " 03/21/2000 - "Western blot analysis showed that during the serotonin-induced contractions, the extent of phosphorylation of the myosin-binding subunit of myosin phosphatase (MBS), one of the major substrates of Rho-kinase, was significantly greater in the spastic than in the control segment and that the increase in MBS phosphorylations was also markedly inhibited by Y-27632. "
4.	Ischemia 02/01/2003 - "The present study examined whether Y-27632 could provide a beneficial effect on hepatic ischemia/reperfusion (I/R)-induced injury through the attenuation of microcirculatory disturbance. " 12/01/2010 - "Administration of Y-27632 (1 μM) before ischemia and during the first 10 min of reperfusion resulted in complete recovery of cardiac function. " 01/01/2008 - "Cell loss of the GCL and thinning of the IPL were significantly attenuated when 100 nmol Y-27632 was administered within three hours of the induction of ischemia. " 11/28/2004 - "The ischemia/reperfusion-induced renal dysfunction was also overcome by postischemic treatment with Y-27632 at 100 microg/kg, i.p. " 02/15/2004 - "In addition, Y-27632 decreased ischemia/reperfusion-induced accumulation of neutrophils in the heart by 45% (P<0.01). "
5.	Edema 01/01/2014 - "Y-27632 (1) inhibited the migration of inflammatory cells into the alveolar space, (2) decreased the production of TNF-α, and (3) attenuated the edema after LTX. " 01/01/2014 - "Pretreatment of the donor lungs and recipient rats with Y-27632 prominently suppressed the post-LTX edema, while the permeability index was only slightly decreased. " 06/01/2005 - "Pretreatment with Y-27632 attenuated both lung edema and neutrophil emigration after LPS. " 11/01/2014 - "To study the effects of inhibiting ROCKs using two known inhibitors, Y27632 and HA1077 (fasudil), administered locally, on nociception and paw edema in rats. " 04/01/2013 - "In addition to the animal study findings, the clinical study findings showed that Y-27632 eye drops effectively improved corneal edema of corneal endothelial dysfunction patients with central edema. "

Related Drugs and Biologics

1.	rho-Associated Kinases
2.	fasudil (AT 877)
3.	Ophthalmic Solutions (Eye Drops)
4.	Plastics
5.	dexpanthenol
6.	Protein Kinases (Protein Kinase)
7.	Myosin Light Chains (Myosin Essential Light Chain)
8.	Actins (F Actin)
9.	Hydroxyproline (4 Hydroxyproline)
10.	Myosin-Light-Chain Phosphatase

Related Therapies and Procedures

1.	Airway Management
2.	Liver Transplantation
3.	Ligation
4.	Intravenous Injections
5.	Drug Therapy (Chemotherapy)